Member Login

Edesa Biotech

Contact Information:

Phone: (805) 488-2800

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases. The company recently reported favorable results from a Phase 2b study of its drug candidate, EB01 (daniluromer), as a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis. Daniluromer is a first-in-class, non-steroidal anti-inflammatory compound that inhibits secretory phospholipase 2 (sPLA2) pro-inflammatory enzymes.


Cookie Notice

This website uses cookies to deliver to you the best experience possible on our website. By continuing to use this site, you are providing us with your consent to ensure you receive such an experience. View our privacy policy to learn more.